Hormonal
Menopause significantly increases cardiovascular risk in women by altering lipid profiles and promoting central adiposity, which worsens coronary artery disease outcomes more than in men.
After menopause, your cardiovascular risk profile changes significantly due to the loss of estrogen. This leads to worse lipid profiles and increased central fat, which disproportionately harms heart health compared to men. If you have diabetes or high blood pressure, your risk of heart failure is significantly higher than a man with the same conditions. Post-menopausal women should prioritize cardiovascular screening and lifestyle interventions tailored to this hormonal change.
lipid profile [HDL- (high-density lipoprotein) and LDL (low-density lipoprotein)-cholesterol as well as triacylglycerols] dramatically worsens after the menopause favouring atherogenesis... T2D worsens the coronary artery disease outcome more in women than in men
Why this rating
Supported by multiple studies cited regarding lipid profiles, adiposity, and clinical outcomes.
Source
Gender, aging and longevity in humans: an update of an intriguing/neglected scenario paving the way to a gender-specific medicine
Rita Ostan et al. · Clinical Science · 2016
DOI 10.1042/cs20160004
More from this paper
- Women live longer than men globally, but this survival advantage is offset by a higher prevalence of disability and age-related diseases in later life, resulting in similar healthy life expectancy between genders.Good
- Dietary restriction (DR) and intermittent fasting (IF) extend lifespan and improve health markers in animal models and humans, with some evidence suggesting greater longevity benefits in females, though IF may be more feasible for women.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →